seasonal allergic rhinitis
Conditions
Interventions
Intervention group have extracted chlorophyll c2 0.7g/day for 12 weeks.
Control group have placebo for 12 week.
Sponsors
Department of Otolaryngology Head and Neck Surgery, Ehime University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are eligible to participate in the study if they had a history of SAR of at least 2years.
Exclusion criteria
Exclusion criteria: Patients are excluded if they had received intranasal or oral prophylactic therapy that season; had known serious renal, cardiac, or hepatic disease; were pregnant or lactating; or had asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary trial outcomes were change in symptoms and change in need for medication between baseline and 4 week after treatment. We assessed symptoms by using the disease-specific Japan Rhinitis Quality of Life Questionnaire (JRQLQ). The JRQLQ has 24 questions in 8 domains of nose and eye symptoms, usual daily activities, outdoor activities, social functioning, sleep problems, general physical problems and emotional function, and the overall QOL. Each questions evaluate symptom on a five-point scale (0 for no symptoms, 1 for mild, 2 for moderately severe, 3 for severe and 4 for very severe symptoms). Medication need was measured using an rescue medication score (RMS), comprising the weekly sum of daily assessments (fexofenadine 60 mg/d, or equivalent [1 point]; fexofenadine 120 mg/d, or equivalent [2 points]; and any form of nasal steroids for SAR [2 points]) (daily range, 0 to 4; weekly range, 0 to 28). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary trial outcomes were change in symptoms and change in need for medication between baseline and 8, 12 week after treatment. | — |
Countries
Japan
Contacts
Public ContactTakashi Fujiwara
Ehime University Hospital Otolaryngology Head and Neck Surgery
Outcome results
None listed